Holen Sie sich die Stockscreener-App
6.56
1.80%
-0.12
Schlusskurs vom Vortag:
$6.68
Offen:
$6.68
24-Stunden-Volumen:
100.28K
Relative Volume:
0.22
Marktkapitalisierung:
$370.21M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-72.89M
KGV:
-2.7107
EPS:
-2.42
Netto-Cashflow:
$-68.47M
1W Leistung:
+5.13%
1M Leistung:
+13.89%
6M Leistung:
-11.47%
1J Leistung:
-42.81%
1-Tages-Spanne:
$6.48
$6.73
1-Wochen-Bereich:
$5.9404
$6.73
52-Wochen-Spanne:
$3.555
$12.92
Astria Therapeutics Inc Stock (ATXS) Company Profile
Firmenname
Astria Therapeutics Inc
Sektor
Branche
Telefon
617-349-1971
Adresse
22 BOSTON WHARF ROAD, BOSTON
Vergleichen Sie ATXS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
6.56 | 362.31M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-01-31 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-29 | Eingeleitet | TD Cowen | Buy |
| 2023-03-28 | Eingeleitet | Evercore ISI | Outperform |
Astria Therapeutics Inc Aktie (ATXS) Neueste Nachrichten
What analysts say about Astria Therapeutics Inc. stockFree Stock Market Forecast Reports - Autocar Professional
What drives Astria Therapeutics Inc. stock priceConsistent double returns - Autocar Professional
Astria Therapeutics Inc. Stock Analysis and ForecastHigh-octane financial growth - jammulinksnews.com
Is Astria Therapeutics Inc. a good long term investmentFree Market Dynamics Reports - jammulinksnews.com
Published on: 2025-07-19 19:06:02 - jammulinksnews.com
Will Astria Therapeutics Inc. stock split in the near futureFree Stock Market Trend Analysis - Newser
why astria therapeutics inc. stock attracts strong analyst attentionPortfolio Boosting Stock Alerts - Newser
How Astria Therapeutics Inc. stock performs during market volatilityTechnical Breakout List - Newser
Why Astria Therapeutics Inc. stock attracts strong analyst attentionFree Professional Portfolio Management - beatles.ru
What makes Astria Therapeutics Inc. stock price move sharplyFree Access to Stock Community - beatles.ru
Astria: Betting On Navenibart In The Crowded HAE Arena - Seeking Alpha
Astria Therapeutics (ATXS) Soars 5.62% on Positive Trial Results - AInvest
Astria Therapeutics Inc (ATXS) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit - BioSpace
Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Recommendation of “Buy” by Analysts - Defense World
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2, 2025 - BioSpace
Trading (ATXS) With Integrated Risk Controls - news.stocktradersdaily.com
(ATXS) Trading Report - news.stocktradersdaily.com
Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit - BioSpace
Astria Therapeutics to Participate in Upcoming Oppenheimer Innov - GuruFocus
Astria CEO Discusses Breakthrough Dermatology Treatments at Major Oppenheimer Summit - Stock Titan
Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress - BioSpace
Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Target Price at $30.00 - Defense World
HC Wainwright Reaffirms “Buy” Rating for Astria Therapeutics (NASDAQ:ATXS) - Defense World
Finanzdaten der Astria Therapeutics Inc-Aktie (ATXS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.32%
1.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):